HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Lin, C.-c. Articles by Peterson, J. Search for Related Content PubMed PubMed Citation Articles by Lin, C.-c. Articles by Peterson, J.

Pharmacokinetics of Pradefovir and PMEA in Healthy Volunteers After Oral Dosing of Pradefovir

From Research and Development, Valeant Pharmaceuticals International, Costa Mesa, California.

The pharmacokinetics of pradefovir and adefovir, 9-(2-phosphonylmethoxyethyl) adenine (PMEA), was evaluated in healthy male volunteers after oral dosing of pradefovir (10, 30, or 60 mg). Pradefovir was absorbed rapidly. The maximum serum concentration, the area under the concentration-time curve between 0 and 96 hours after dosing (AUC_0-96), and the area under the plasma concentration versus time curve from time 0 to infinity (AUC_0-) of pradefovir and PMEA increased with the dose of pradefovir. The ratio of PMEA to pradefovir for AUC_0-96 and AUC_0- ranged from 1.4 to 1.8. Renal clearance of pradefovir (18-31 L/h) increased with the dose of pradefovir and was greater than glomerular filtration. The fraction of total body clearance due to renal clearance was low (0.045 to 0.083), suggesting that metabolic clearance played a significant role in the clearance of pradefovir in man. In addition, an evaluation of the food effect was conducted at the 30-mg dose. The results indicate that food intake has no effect on the extent of exposure of pradefovir and PMEA but may decrease the rate of systemic availability of PMEA.

Key Words: Pradefovir • adefovir dipivoxil • pharmacokinetics • hepatitis B • antiviral

Address for reprints: Dr Chin-chung Lin, Valeant Pharmaceuticals International, 3300 Hyland Avenue, Costa Mesa, CA 92626.

This article has been cited by other articles:

				C.-c. Lin, C. Fang, S. Benetton, G.-f. Xu, and L.-T. Yeh Metabolic Activation of Pradefovir by CYP3A4 and Its Potential as an Inhibitor or Inducer. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2926 - 2931. [Abstract] [Full Text] [PDF]